PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-30.37%
Negative gross profit growth while AXSM is at 90.41%. Joel Greenblatt would examine cost competitiveness or demand decline.
-24.83%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.83%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-17.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12.12%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-9.09%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.06%
Share count expansion well above AXSM's 6.71%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.04%
Diluted share count expanding well above AXSM's 6.71%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-120.47%
Negative OCF growth while AXSM is at 32.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-120.93%
Negative FCF growth while AXSM is at 32.43%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-252.09%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.56%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
77.71%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
99.67%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
85.97%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
69.72%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
173.45%
Equity/share CAGR of 173.45% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-62.01%
Negative 5Y equity/share growth while AXSM is at 429.59%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
56.61%
Below 50% of AXSM's 1805.02%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Negative asset growth while AXSM invests at 87.73%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-13.24%
We have a declining book value while AXSM shows 870.19%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-1.77%
We’re deleveraging while AXSM stands at 0.17%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
45.24%
We increase R&D while AXSM cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-4.95%
We cut SG&A while AXSM invests at 31.23%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.